PTKFY Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of 7.48% compared to PT Kalbe Farma Tbk's net margin of --. PT Kalbe Farma Tbk's return on equity of 14.27% beat CEL-SCI Corp.'s return on equity of -266.61%.

PT Kalbe Farma Tbk has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that CEL-SCI Corp. has higher upside potential than PT Kalbe Farma Tbk, analysts believe CEL-SCI Corp. is more attractive than PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk has a beta of -0.248, which suggesting that the stock is 124.802% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

PT Kalbe Farma Tbk has a quarterly dividend of $0.44 per share corresponding to a yield of 3.45%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PT Kalbe Farma Tbk pays 32.04% of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend. PT Kalbe Farma Tbk's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

PT Kalbe Farma Tbk quarterly revenues are $540M, which are larger than CEL-SCI Corp. quarterly revenues of --. PT Kalbe Farma Tbk's net income of $40.4M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, PT Kalbe Farma Tbk's price-to-earnings ratio is 13.63x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PT Kalbe Farma Tbk is 1.39x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of 7.48% compared to PT Kalbe Farma Tbk's net margin of -953.4%. PT Kalbe Farma Tbk's return on equity of 14.27% beat IGC Pharma, Inc.'s return on equity of -94.42%.

PT Kalbe Farma Tbk has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1052.93%. Given that IGC Pharma, Inc. has higher upside potential than PT Kalbe Farma Tbk, analysts believe IGC Pharma, Inc. is more attractive than PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk has a beta of -0.248, which suggesting that the stock is 124.802% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

PT Kalbe Farma Tbk has a quarterly dividend of $0.44 per share corresponding to a yield of 3.45%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PT Kalbe Farma Tbk pays 32.04% of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend. PT Kalbe Farma Tbk's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

PT Kalbe Farma Tbk quarterly revenues are $540M, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. PT Kalbe Farma Tbk's net income of $40.4M is higher than IGC Pharma, Inc.'s net income of -$1.8M. Notably, PT Kalbe Farma Tbk's price-to-earnings ratio is 13.63x while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PT Kalbe Farma Tbk is 1.39x versus 25.22x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of 7.48% compared to PT Kalbe Farma Tbk's net margin of -255.85%. PT Kalbe Farma Tbk's return on equity of 14.27% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

PT Kalbe Farma Tbk has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -71.19%. Given that NovaBay Pharmaceuticals, Inc. has higher upside potential than PT Kalbe Farma Tbk, analysts believe NovaBay Pharmaceuticals, Inc. is more attractive than PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk has a beta of -0.248, which suggesting that the stock is 124.802% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

PT Kalbe Farma Tbk has a quarterly dividend of $0.44 per share corresponding to a yield of 3.45%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. PT Kalbe Farma Tbk pays 32.04% of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. PT Kalbe Farma Tbk's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

PT Kalbe Farma Tbk quarterly revenues are $540M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. PT Kalbe Farma Tbk's net income of $40.4M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, PT Kalbe Farma Tbk's price-to-earnings ratio is 13.63x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 4.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PT Kalbe Farma Tbk is 1.39x versus 5.73x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of 7.48% compared to PT Kalbe Farma Tbk's net margin of 13.19%. PT Kalbe Farma Tbk's return on equity of 14.27% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

PT Kalbe Farma Tbk has a consensus price target of --, signalling downside risk potential of --. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 511.11%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than PT Kalbe Farma Tbk, analysts believe Protalix Biotherapeutics, Inc. is more attractive than PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk has a beta of -0.248, which suggesting that the stock is 124.802% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

PT Kalbe Farma Tbk has a quarterly dividend of $0.44 per share corresponding to a yield of 3.45%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PT Kalbe Farma Tbk pays 32.04% of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend. PT Kalbe Farma Tbk's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

PT Kalbe Farma Tbk quarterly revenues are $540M, which are larger than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. PT Kalbe Farma Tbk's net income of $40.4M is higher than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, PT Kalbe Farma Tbk's price-to-earnings ratio is 13.63x while Protalix Biotherapeutics, Inc.'s PE ratio is 25.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PT Kalbe Farma Tbk is 1.39x versus 2.29x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.